Showing results (221-230 of 771) with videos related to
Sort By:
Pageof 78
Current Pharmaceutical Biotechnology|March 2, 2023
Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A ReviewYashumati Ratan, Aishwarya Rajput, Vivek Jain, et al.Journal of Clinical Microbiology|September 24, 2020
Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral TherapySonia Bakkour, Xutao Deng, Peter Bacchetti, et al.Ebiomedicine|June 1, 2022
Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS eventsSergio Serrano-Villar, Kunling Wu, Peter W Hunt, et al.AIDS Research and Human Retroviruses|September 9, 2016
High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 ViremiaRebecca Nedellec, Joshua T Herbeck, Peter W Hunt, et al.Atherosclerosis|May 29, 2013
Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individualsRushi V Parikh, Rebecca Scherzer, Carl Grunfeld, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 16, 2014
Cutting edge: An antibody recognizing ancestral endogenous virus glycoproteins mediates antibody-dependent cellular cytotoxicity on HIV-1-infected cellsHenri-Alexandre Michaud, Devi SenGupta, Miguel de Mulder, et al.AIDS (London, England)|January 20, 2011
N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patientsDaniel A Duprez, Jacqueline Neuhaus, Russell Tracy, et al.AIDS (London, England)|March 3, 2015
Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32Timothy J Henrich, Emily Hanhauser, Zixin Hu, et al.Pathogens & Immunity|July 8, 2022
Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic StudiesMichael J Peluso, Khamal Anglin, Matthew S Durstenfeld, et al.The Journal of Infectious Diseases|April 20, 2011
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapyPeter W Hunt, Jeffrey N Martin, Elizabeth Sinclair, et al.Pageof 78